OMER
NASDAQ
$9.63
Omeros Corporation (OMER)
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Sector:
Healthcare
Industry:
Biotechnology
Hold
Target: $33 (+242.68%)
Market Cap
$747M
PEG Ratio
0.81
Profit Margin
871%
P/E Ratio
9.26
Price Chart
Valuation
Market Cap$747M
P/E9.26
Forward P/E58.14
PEG0.81
P/S76.82
P/B8.44
Profitability
Total Revenue (TTM)$9.89M
Gross Profit (TTM)-$19M
EBITDA-$104M
Profit Margin871%
Operating Margin-176.1%
EPS$1.12
Financial Health
Free Cash Flow Yield-12.69%
Growth & Risk
Revenue 5Y CAGR-32.64%
FCF 5Y CAGR-6.33%
Beta (5Y)1.37
Sharpe Ratio1.11